Royal DSM provided earnings guidance for the year 2022. DSM maintains ambitious mid-term profit targets as a Health, Nutrition & Bioscience company of mid-single digit % organic sales growth, an above 20% Adjusted EBITDA margin, and high-single digit % Adjusted EBITDA growth, supported by its strong innovation pipeline. Positive outlook for 2022 in line with mid-term strategic targets.